Daratumumab (Subcutaneously) Clinical Trials
2 recruitingDrug
Phase 21Not Applicable1
Showing 1–2 of 2 trials
Recruiting
Not Applicable
Daratumumab for Late Antibody-Mediated Rejection
Acute Rejection (AR) of Transplanted KidneyKidney Tansplant
University Hospital, Martin20 enrolled1 locationNCT07081126
Recruiting
Phase 2
An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L
Primary Plasma Cell Leukemia
Hellenic Society of Hematology43 enrolled7 locationsNCT06636552